Covidien plc (COV) Completes Patient Enrollment in Iliac Stent Clinical Study Series
2/20/2013 10:33:49 AM
MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the completion of patient enrollment in its iliac stent clinical study series. The series is composed of two prospective, multinational, multicenter studies - VISIBILITY Iliac and DURABILITY Iliac.
comments powered by